57017-95-5

Usage

Uses

Used in Pharmaceutical Industry:
Methyl 3-chloro-4-hydroxyphenylacetate is used as a reagent for the preparation of benzenesulfonamide derivatives, which are important in the development of ATP citrate lyase inhibitors. These inhibitors play a crucial role in targeting metabolic pathways in cancer cells, making them potential candidates for cancer treatment and therapy.

InChI:InChI=1/C9H9ClO3/c1-13-9(12)5-6-2-3-8(11)7(10)4-6/h2-4,11H,5H2,1H3

Upstream product

• 67-56-1 methanol 
• 7569-58-6 2-(3-chloro-4-methoxyphenyl)acetonitrile 
• 33697-81-3 (3-chloro-4-hydroxy-phenyl)-acetic acid 
• 18107-18-1 diazomethyl-trimethyl-silane 
• 13719-57-8 3-chloro-4-methoxybenzyl chloride 
• 141805-68-7 N-(3-Chloro-4-hydroxyphenylacetyl)fumarate 
• 766-51-8 2-Chloroanisole 

Downstream Products

• 60736-82-5 3-chloro-4-(4'-isobutylbenzyloxy)-phenylacetic acid 
• 60736-67-6 3-chloro-4-(3'-chloro-4'-allyloxybenzyloxy)-phenylacetic acid 
• 60736-76-7 3-chloro-4-(4'-isobutoxybenzyloxy)-phenylacetic acid 
• 60736-75-6 3-chloro-4-(4' isopropoxy benzyloxy) phenylacetic acid 
• 194793-04-9 methyl 3-chloro-4-(3-bromopropyloxy)-phenylacetate 
• 927178-35-6 3-(2-chloro-4-methoxycarbonylmethyl-phenoxymethyl)-5-phenylisoxazole-4-carboxylic acid tert-butyl ester 
• 870289-04-6 [3-chloro-4-(3,5-dibromobenzyloxy)phenyl]acetic acid methyl ester 
• 905991-54-0 methyl (4-{2-[(tert-butoxycarbonyl)(methyl)amino]ethoxy}-3-chlorophenyl)acetate 
• 905991-57-3 methyl (4-{3-[(tert-butoxycarbonyl)(methyl)amino]propoxy}-3-chlorophenyl)acetate 
• 870289-05-7 [3-chloro-4-(3,5-dibromobenzylsulfanyl)phenyl]acetic acid methyl ester 
• 905991-67-5 (3-chloro-4-{2-[(5-[1,2]dithiolan-3-yl-pentanoyl)-methyl-amino]-ethoxy}-phenyl)-acetic acid methyl ester 
• 905991-71-1 (3-chloro-4-{3-[(5-[1,2]dithiolan-3-yl-pentanoyl)-methyl-amino]-propoxy}-phenyl)-acetic acid methyl ester 
• 890137-67-4 [4-(4,4''-bis-trifluoromethyl-[1,1';3',1'']terphenyl-5'-ylmethoxy)-3-chloro-phenyl]-acetic acid methyl ester 
• 890137-68-5 [4-(4,4''-bis-trifluoromethyl-[1,1';3',1'']terphenyl-5'-ylmethylsulfanyl)-3-chloro-phenyl]-acetic acid methyl ester 

Relevant academic research and scientific papers

Design and synthesis of a screening library using the natural product scaffold 3-chloro-4-hydroxyphenylacetic acid

The fungal metabolite 3-chloro-4-hydroxyphenylacetic acid (1) was utilized in the generation of a unique drug-like screening library using parallel solution-phase synthesis. A 20-membered amide library (3-22) was generated by first converting 1 to methyl (3-chloro-4-hydroxyphenyl)acetate (2), then reacting this scaffold with a diverse series of primary amines via a solvent-free aminolysis procedure. The structures of the synthetic analogues (3-22) were elucidated by spectroscopic data analysis. The structures of compounds 8, 12, and 22 were confirmed by single X-ray crystallographic analysis. All compounds were evaluated for cytotoxicity against a human prostate cancer cell line (LNCaP) and for antiparasitic activity toward Trypanosoma brucei brucei and Plasmodium falciparum and showed no significant activity at 10 μM. The library was also tested for effects on the lipid content of LNCaP and PC-3 prostate cancer cells, and it was demonstrated that the fluorobenzyl analogues (12-14) significantly reduced cellular phospholipid and neutral lipid levels.

CHEMOSELECTIVE METHYLENE HYDROXYLATION IN AROMATIC MOLECULES

A chemoselective and reactive Mn(CF3-PDP) catalyst system that enables for the first time the strategic advantages of late-stage aliphatic C—H hydroxylation to be leveraged in aromatic compounds. This discovery will benefit small molecule therapeutics by enabling the rapid diversification of aromatic drugs and natural products and identification of their metabolites.

Aryl or N-heteroaryl Substituted Methanesulfonamide Derivatives as Vanilloid Receptor Ligands

The invention relates to aryl or N-heteroaryl substituted methanesulfonamide derivatives as vanilloid receptor ligands, to pharmaceutical compositions containing these compounds and also to these compounds for use in the treatment and/or prophylaxis of pain and further diseases and/or disorders.

ARYL OR N-HETEROARYL SUBSTITUTED METHANESULFONAMIDE DERIVATIVES AS VANILLOID RECEPTOR LIGANDS

The invention relates to aryl or N-heteroaryl substituted methanesulfonamide derivatives of Formula (I) as vanilloid receptor ligands, to pharmaceutical compositions containing these compounds and also to these compounds for use in the treatment and/or prophylaxis of pain and further diseases and/or disorders.

Amine Substituted Methanesulfonamide Derivatives as Vanilloid Receptor Ligands

The invention relates to amine substituted methanesulfonamide derivatives as vanilloid receptor ligands, to pharmaceutical compositions containing these compounds and also to these compounds for use in the treatment and/or prophylaxis of pain and further diseases and/or disorders.

AMINE SUBSTITUTED METHANESULFONAMIDE DERIVATIVES AS VANILLOID RECEPTOR LIGANDS

The invention relates to amine substituted methanesulfonamide derivatives of formula (I) as vanilloid receptor ligands, to pharmaceutical compositions containing these compounds and also to these compounds for use in the treatment and/or prophylaxis of pain and further diseases and/or disorders.

SUBSTITUTED PYRAZOLYL-BASED CARBOXAMIDE AND UREA DERIVATIVES BEARING A PHENYL MOIETY SUBSTITUTED WITH AN N-CONTAINING GROUP AS VANILLOID RECEPTOR LIGANDS

The invention relates to substituted pyrazolyl-based carboxamide and urea derivatives of formula (R) bearing a phenyl moiety substituted with an N-containing group as vanilloid receptor ligands, to pharmaceutical compositions containing these compounds and also to these compounds for use in the treatment and/or prophylaxis of pain and further diseases and/or disorders.

CHEMICAL COMPOUNDS 785

DGAT-1 inhibitor compounds of formula (I), pharmaceutically-acceptable salts and pro-drugs thereof are described, together with pharmaceutical compositions, processes for making them and their use in treating, for example, obesity wherein, for example, r is 0 or 1 and X1 is linear (1-3C)alkyl; q is 0 or 1 and X2 is fluoro, chloro or (1-3C)alkyl; Y1 is selected from fluoro, chloro, bromo, cyano, (1-3C)alkyl and (1-2C)alkoxy; n is 0, 1 or 2 and Y2 is fluoro, chloro or (1-3C)alkyl; p is 0, 1 or 2 and Y3 is (1-3C)alkyl or forms a (3-5C)cycloalkyl ring; Z is carboxy or —CONHSO2Me or —CONRbRc wherein Rb and Rc are independently selected, for example, from hydrogen and (1-4C)alkyl or Rb and Rc are linked so as to form a morpholine ring or a (4-6C)heterocyclic ring and when Z is —CONRbRc the Rb and Rc groups may be optionally substituted by carboxy.

NOVEL 3-PHENYL ACRYLIC ACID COMPOUND ACTIVATORS OF TYPE PPAR RECEPTORS AND PHARMACEUTICAL/COSMETIC COMPOSITIONS COMPRISED THEREOF

Novel 3-phenyl acrylic acid compounds have the following general formula (I): and are formulated into pharmaceutical compositions for administration in human or veterinary medicine (in dermatology, as well as in the field of cardiovascular diseases, immune diseases and/or diseases associated with lipid metabolism), or into cosmetic compositions.

BIPHENYL DERIVATIVES AS MODULATORS OF THE HISTAMINE-H3 RECEPTOR USEFUL FOR THE TREATMENT OF DISORDERS RELATED THERETO

Biphenyl derivatives of Formula (Ia) and pharmaceutical compositions thereof that modulate the activity of the H3 histamine receptor. (Ia) Compounds of the present invention and pharmaceutical compositions thereof are directed to methods useful in the treatment of histamine H3-associated disorders, such as cognitive disorders, epilepsy, brain trauma, depression, obesity, disorders of sleep and wakefulness, such as narcolepsy, shift-work syndrome, drowsiness as a side effect from a medication, maintenance of vigilance to aid in completion of tasks and the like, cataplexy, hypersomnia, somnolence syndrome, jet lag, sleep apnea and the like, attention deficit hyperactivity disorder (ADHD), schizophrenia, allergies, allergic responses in the upper airway, allergic rhinitis, nasal congestion, dementia, Alzheimer's disease, pain and the like.